Related references
Note: Only part of the references are listed.Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Jonathan W. Riess et al.
CLINICAL LUNG CANCER (2021)
Monoclonal antibodies as an addition to current myeloma therapy strategies
Maxime Jullien et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020
Ivo Demel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers
Yumi Oh et al.
CANCER LETTERS (2021)
Therapeutic potential of antagomiRs in haematological and oncological neoplasms
Vanessa Innao et al.
EUROPEAN JOURNAL OF CANCER CARE (2020)
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K. Rowinsky et al.
INVESTIGATIONAL NEW DRUGS (2020)
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
Richa Bajpai et al.
NATURE COMMUNICATIONS (2020)
Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma
Liang Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Anticancer and Immunomodulatory Activities of a Novel Water-Soluble Derivative of Ellipticine
Regiane Costa de Oliveira et al.
MOLECULES (2020)
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies
A. Allegra et al.
ONCOLOGY REPORTS (2020)
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
Cesarina Giallongo et al.
CANCERS (2020)
Sulphamoylated Estradiol Analogue Induces Reactive Oxygen Species Generation to Exert Its Antiproliferative Activity in Breast Cancer Cell Lines
Maphuti T. Lebelo et al.
MOLECULES (2020)
Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways
Xiuhua Wu et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Antitumor Therapy under Hypoxic Microenvironment by the Combination of 2-Methoxyestradiol and Sodium Dichloroacetate on Human Non-Small-Cell Lung Cancer
Yair Romero et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling
Purab Pal et al.
Oncotarget (2020)
A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
Haojie Jin et al.
ELIFE (2020)
Amino acid depletion triggered by.-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
Debora Soncini et al.
BLOOD ADVANCES (2020)
Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin
Amita Vaidya et al.
THERANOSTICS (2020)
Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment
Xiaonan Zhang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
Concetta Conticello et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma
Liling Jiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Evodiamine inactivates NF-κB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo
Qi Guo et al.
ONCOTARGETS AND THERAPY (2019)
Evodiamine Selectively Inhibits Multiple Myeloma Cell Growth by Triggering Activation of Intrinsic Apoptosis Pathway
Qing Fang et al.
ONCOTARGETS AND THERAPY (2019)
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis
Lenka Besse et al.
HAEMATOLOGICA (2019)
Mitochondrial DNA stress signalling protects the nuclear genome
Zheng Wu et al.
NATURE METABOLISM (2019)
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma
Korbinian N. Kropp et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Nanobodies and Cancer: Current Status and New Perspectives
Alessandro Allegra et al.
CANCER INVESTIGATION (2018)
Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells
Yi Zhao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Deubiquitinase inhibitor b-AP15 activates endoplasmic reticulum (ER) stress and inhibits Wnt/Notch1 signaling pathway leading to the reduction of cell survival in hepatocellular carcinoma cells
Youming Ding et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies
Robin Didier et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and Check for mitochondrial damage
Xiaonan Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Standardisation of minimal residual disease in multiple myeloma
V. Innao et al.
EUROPEAN JOURNAL OF CANCER CARE (2017)
Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
Xin Zhan et al.
ONCOTARGET (2017)
A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers
Jianyu Cai et al.
ONCOTARGET (2017)
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
Ravyn M. Thompson et al.
ONCOTARGET (2017)
Management of multiple myeloma in the relapsed/refractory patient
Pieter Sonneveld
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway
Farhad Poupel et al.
INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE (2017)
Mitochondrial DNA in innate immune responses and inflammatory pathology
A. Phillip West et al.
NATURE REVIEWS IMMUNOLOGY (2017)
A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
Chao Qiu et al.
CHEMISTRY CENTRAL JOURNAL (2016)
The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF- and TRAIL-induced apoptosis
Mohamed El-Mesery et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies
Pasquale Aragona et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstroom macroglobulinaemia tumour cells
Kasyapa Chitta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells
Juliane Liese et al.
CANCER LETTERS (2015)
Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells
Sofie Steinwascher et al.
CANCER LETTERS (2015)
Vaccination of multiple myeloma: Current strategies and future prospects
Alessandro Allegra et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia
Daniela Opel et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Ravi K. Amaravadi et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis
Stephanie Hehlgans et al.
RADIATION ONCOLOGY (2015)
Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death
V. Marschall et al.
CELL DEATH & DISEASE (2015)
Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis
S. Cristofanon et al.
CELL DEATH & DISEASE (2015)
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
Andrew R. Lavik et al.
ONCOTARGET (2015)
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance
Ze Tian et al.
BLOOD (2014)
Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells
Vanessa Bake et al.
CANCER LETTERS (2014)
Dihydroartemisinin induces apoptosis in colorectal cancer cells through the mitochondria-dependent pathway
Min Lu et al.
TUMOR BIOLOGY (2014)
Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
Xenofon Papanikolaou et al.
ONCOTARGET (2014)
Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells
I. S. Song et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro
Haiting Mao et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013)
Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo
Jie Lin et al.
ONCOLOGY REPORTS (2013)
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
In-Sung Song et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2013)
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner
Aisha Masood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Anne Le et al.
CELL METABOLISM (2012)
Proteasome deubiquitinases as novel targets for cancer therapy
Padraig D'Arcy et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells
Chenjuan Zhou et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
ABT-737 is highly effective against molecular subgroups of multiple myeloma
Linda Bodet et al.
BLOOD (2011)
BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non-small Cell Lung Carcinoma In Vitro
Wenyan Li et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation (vol 18, pg 207, 2010)
Jian-Bin Wang et al.
CANCER CELL (2010)
Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques
Ying-Ying Lu et al.
JOURNAL OF BIOMEDICAL OPTICS (2010)
Smac mimetics as new cancer therapeutics
Derrick J. Chen et al.
ANTI-CANCER DRUGS (2009)
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737
Paula Hauck et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpa
Junlin Jiang et al.
MOLECULES (2009)
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells
Michael P. Kline et al.
EXPERIMENTAL HEMATOLOGY (2008)
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma
Erming Tian et al.
MOLECULAR CANCER THERAPEUTICS (2008)
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Christian A. Hassig et al.
MOLECULAR CANCER THERAPEUTICS (2008)
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling
Rentian Feng et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage
Rentian Feng et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
Patricia Perez-Galan et al.
BLOOD (2007)
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Dharminder Chauhan et al.
BLOOD (2007)
Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic
Haiying Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion
Xiu-Hua Wu et al.
ANTI-CANCER DRUGS (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells
D Chauhan et al.
CANCER RESEARCH (2005)
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance
H Yasui et al.
CANCER RESEARCH (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis
H Erdal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
D Chauhan et al.
BLOOD (2004)
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
XY Pei et al.
CLINICAL CANCER RESEARCH (2004)
The triterpenoid CDDO induces apoptosis in refractory CLL B cells
IM Pedersen et al.
BLOOD (2002)
The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells
TA Stadheim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia
M Konopleva et al.
BLOOD (2002)
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
CY Du et al.
CELL (2000)
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
AM Verhagen et al.
CELL (2000)
Share Paper
